BVAXF (BioVaxys Technology) Buyback Yield % : -20.66 (As of Apr. 19, 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

BioVaxys Technology's current buyback yield was -20.66%.

BioVaxys Technology Buyback Yield % Historical Data

The historical data trend for BioVaxys Technology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Buyback Yield % Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Buyback Yield %

Get a 7-Day Free Trial

-9.71

-8.90

-4.88

-42.69

-16.45

BioVaxys Technology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Buyback Yield %	Get a 7-Day Free Trial															-19.19	-10.65	-15.35	-17.23	-17.59

Competitive Comparison of BioVaxys Technology's Buyback Yield %

For the Biotechnology subindustry, BioVaxys Technology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVaxys Technology's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

BioVaxys Technology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

BioVaxys Technology's Buyback Yield for the fiscal year that ended in Oct. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	2.298)	/	13.9676914
	=	-16.45%

BioVaxys Technology's annualized Buyback Yield for the quarter that ended in Jan. 2025 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	2.168)		/	13.33257984
	=	-16.26%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

BioVaxys Technology Buyback Yield % Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.